Fidaxomicin (Dificid) for Clostridium difficile infection.

continuing educat ion for pharmacists

Goal. The goal of this lesson is to provide a review of Clostridium difficile infection (CDI) to include epidemiology and pathophysiology of the disease, risk factors, transmission, clinical diagnosis, and adult treatment. In addition, a new entity and treatment option for CDI, fidaxomicin (Dificid®), will be reviewed. Surgical and nonpharmacological treatment will not be discussed in this lesson.

Stability and Recovery of DIFICID® (Fidaxomicin) 200-mg Crushed Tablet Preparations from Three Delivery Vehicles, and Administration of an Aqueous Dispersion via Nasogastric Tube

Fidaxomicin is approved for the treatment of adults with Clostridium difficile-associated diarrhea, many of whom have difficulty swallowing an intact tablet. The study objective was to evaluate the stability and recovery of crushed DIFICID(®) (fidaxomicin) 200-mg tablets dispersed in water, applesauce, or Ensure(®) brand liquid nutritional supplement, and to determine the recovery of fidaxomici...

Fidaxomicin is a Superior Treatment to Vancomycin for Recurrent Clostridium Difficile Infection

467Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections

A case report of successful management of clostridium difficile colitis with antegrade Fidaxomicin through a mucous fistula obviating the need for subtotal colectomy

INTRODUCTION Clostridium difficile is the most common cause of healthcare-associated infections and can have devastating morbidity and mortality. Traditional treatment algorithms involve intravenous metronidazole and enteric metronidazole or vancomycin. Fidaxomicin (DificidR) targets "switch regions" within RNA polymerases and effectively kills clostridium difficile bacteria and is typically ad...